Related Experiment Video
Updated: Mar 26, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Genetics and Epigenetics of Chronic Allograft Dysfunction in Kidney Transplants
Sepideh Zununi Vahed, Nasser Samadi, Elmira Mostafidi
1Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ardalan34@yahoo.com.
Abstract:
Chronic allograft dysfunction is the most common cause of allograft lost. Chronic allograft dysfunction happens as a result of complex interactions at the molecular and cellular levels. Genetic and environmental factors both influence the evolution and progression of the chronic allograft dysfunction. Epigenetic modification could be considered as a therapeutically modifiable element to pause the fibrosis process through novel strategies. In this review, the PubMed database was searched for English-language articles on these new areas.
Insights
Chronic allograft dysfunction, a major cause of organ transplant loss, involves complex molecular and cellular interactions. Epigenetic modifications offer a potential therapeutic target to halt the fibrotic process.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Chronic allograft dysfunction (CAD) is the primary cause of long-term organ transplant failure.
- CAD arises from intricate molecular and cellular interactions.
- Both genetic and environmental factors contribute to CAD progression.
Purpose of the Study:
- To review the role of epigenetic modifications in CAD.
- To explore novel therapeutic strategies targeting fibrosis in CAD.
- To identify potential modifiable elements for halting fibrotic processes.
Main Methods:
- A comprehensive literature search was conducted on the PubMed database.
- English-language articles focusing on novel strategies for CAD and epigenetics were included.
- The review synthesized current knowledge on molecular and cellular mechanisms of CAD.
Main Results:
- Epigenetic modifications are implicated in the development and progression of CAD.
- These modifications represent a therapeutically targetable mechanism.
- Targeting epigenetic pathways may offer a strategy to mitigate fibrosis in allografts.
Conclusions:
- Epigenetic modifications are crucial in the pathogenesis of chronic allograft dysfunction.
- Modulating epigenetic mechanisms presents a promising therapeutic avenue to prevent or slow allograft fibrosis.
- Further research into novel epigenetic strategies is warranted for improving transplant outcomes.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cell-mediated Immune Responses
Chronic Kidney Disease I: Introduction

